Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02880319 · ClinicalTrials.gov registry record · Phase 2
Evaluating Stereotactic Body Radiation Therapy for Oligometastatic Disease of the Bone
A Phase 2 study of Bone Cancer, sponsored by Dana-Farber Cancer Institute.
- Active
- Registry status
- Phase 2
- Development phase
- 150
- Enrollment target
- 1
- Study location
NCT02880319: Active Phase 2 study of Bone Cancer, sponsored by Dana-Farber Cancer Institute.
NCT02880319 is a Phase 2 study of Bone Cancer that is active but no longer recruiting, run by Dana-Farber Cancer Institute. The registered enrollment target is 150 participants, below the 686-participant average among 3 other Bone Cancer trials with a reported enrollment target (78% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02880319, a Phase 2 study of Bone Cancer, is active but no longer recruiting, sponsored by Dana-Farber Cancer Institute.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 150 participants
- Enrollment target
- 1
- Study location
Study Summary
This research study is studying a form of radiation therapy called stereotactic body radiation therapy or SBRT as a possible treatment for Cancer that has spread to the spine or other bone
Primary Outcome
The 6-month local control rate is the proportion of patients free of local failure at 6 months after stereotactic body radiation therapy (SBRT). Local failure is defined as the presence of biopsy-proven recurrence or radiologic scans that demonstrate progression at the treated sites.
Conditions Studied
Interventions
- DRUG Stereotactic Body Radiation Therapy (SBRT)
- DEVICE Stereotactic Linear Accelerator
Study Locations (1)
Massachusetts
- Dana Farber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2016-11-29 |
| Est. Completion | 2027-05 |
| Phase | Phase 2 |
What the registry record for NCT02880319 still lists
NCT02880319 is an interventional study that assigns participants to a tested intervention. The registered 150 participants enrollment target is mid-sized for trials with a published cap, below the 686-participant average among 3 other Bone Cancer trials with a reported enrollment target (78% lower).
The record links to 1 condition, with Bone Cancer appearing as the primary indexed condition, and to 2 interventions - of which Stereotactic Body Radiation Therapy (SBRT) is the first listed.
NCT02880319 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT02880319 about?
NCT02880319 is a clinical study titled "Evaluating Stereotactic Body Radiation Therapy for Oligometastatic Disease of the Bone". This research study is studying a form of radiation therapy called stereotactic body radiation therapy or SBRT as a possible treatment for Cancer that has spread to the spine or other bone
What is the current status of trial NCT02880319?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 150 participants. The study started on 2016-11-29. Estimated completion is 2027-05.
What conditions does trial NCT02880319 study?
This clinical trial studies the following conditions: Bone Cancer.
What interventions are being tested in trial NCT02880319?
The interventions under investigation include: Stereotactic Body Radiation Therapy (SBRT) (DRUG), Stereotactic Linear Accelerator (DEVICE).
Who is sponsoring clinical trial NCT02880319?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02880319 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Bone Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Osteosarcoma Maintenance Therapy With OST31-164
ACTIVE NOT RECRUITING · Phase 2
-
Therapeutic Angiotensin-(1-7) in Treating Patients With Metastatic Sarcoma That Cannot Be Removed By Surgery
COMPLETED · Phase 2
-
Genetic Analysis of Pheochromocytomas, Paragangliomas and Associated Conditions
RECRUITING
-
Liposomal Doxorubicin in Treating Children With Refractory Solid Tumors
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00412594 · 150 participants · Phase 2
Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia
- NCT01484730 · 150 participants
A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion
- NCT01985919 · 150 participants
Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples
- NCT02016248 · 150 participants · NA
SBRT Boost for Unfavorable Prostate Cancer'
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI